Characterization of Eleven Important Transplantable Murine Tumors from the Standpoint of Morphology, Pyrimidine Biosynthesis and Responsiveness to Pyrimidine Antimetabolites

[1]  J. Karle,et al.  Effect of plasma concentrations of uridine on pyrimidine biosynthesis in cultured L1210 cells. , 1984, The Journal of biological chemistry.

[2]  Y. Zhen,et al.  Effects of acivicin and dipyridamole on hepatoma 3924A cells. , 1983, Cancer research.

[3]  T. Kensler,et al.  Effects of acivicin and PALA, singly and in combination, on de novo pyrimidine biosynthesis. , 1982, Advances in enzyme regulation.

[4]  T. Kensler,et al.  A facile tritium release assay for mammalian L-dihydroorotate dehydrogenase. , 1981, Analytical biochemistry.

[5]  D. Kufe,et al.  Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. , 1981, Cancer research.

[6]  T. Kensler,et al.  Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. , 1981, Cancer research.

[7]  T. Kensler,et al.  Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma. , 1981, Cancer research.

[8]  T. Kensler,et al.  Chemotherapeutic inhibitors of the enzymes of the de novo pyrimidine pathway. , 1981, Advances in pharmacology and chemotherapy.

[9]  H. Zalkin,et al.  Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). , 1980, The Journal of biological chemistry.

[10]  M. E. Jones,et al.  Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. , 1980, Annual review of biochemistry.

[11]  R. Christopherson,et al.  The effects of pH and inhibitors upon the catalytic activity of the dihydroorotase of multienzymatic protein pyr1-3 from mouse Ehrlich ascites carcinoma. , 1980, The Journal of biological chemistry.

[12]  J. Macdonald,et al.  Physiological and pharmacological determinants of sensitivity and resistance to 5-fluorouracil in lower animals and man. , 1980, Advances in pharmacology and chemotherapy.

[13]  D. J. Adamson,et al.  Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone. , 1979, Cancer research.

[14]  A. Jakubowski,et al.  Pyrazofurin metabolism, enzyme inhibition, and resistance in L5178Y cells. , 1979, Cancer research.

[15]  D. Vistica,et al.  Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA). , 1979, Cancer treatment reports.

[16]  R. Handschumacher,et al.  Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate. , 1979, Cancer research.

[17]  R. Handschumacher,et al.  Clinical, Biological, and Biochemical Effects of Pyrazofurin , 1978 .

[18]  S. R. May,et al.  Inhibition by barbituric acid and its derivatives of the enzymes in rat brain which participate in the synthesis of pyrimidine ribotides. , 1978, Biochemical pharmacology.

[19]  H. Weinfeld,et al.  [13] CTP synthetase of bovine calf liver , 1978 .

[20]  R. B. Dunlap.  [14] TMP synthetase from lactobacillus casei , 1978 .

[21]  M. Mori,et al.  [17] A multienzyme complex of carbamoyl-phosphate synthase (glutamine): Aspartate carbamoyltransferase: Dihydoorotase (rat ascites hepatoma cells and rat liver) , 1978 .

[22]  R. Benjamin,et al.  Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in man. , 1978, Drug metabolism reviews.

[23]  V. Devita,et al.  New anticancer drugs. , 1978, Antibiotics and chemotherapy.

[24]  T. Traut,et al.  Kinetic and conformational studies of the orotate phosphoribosyltransferase:orotidine-5'-phosphate decarboxylase enzyme complex from mouse Ehrlich ascites cells. , 1977, The Journal of biological chemistry.

[25]  J. Roboz,et al.  Pharmacological and biochemical effects of pyrazofurin in humans. , 1977, Cancer research.

[26]  R. Hamill,et al.  BIOCHEMISTRY AND BIOLOGICAL EFFECTS OF THE PYRAZOFURINS * (PYRAZOMYCINS): INITIAL CLINICAL TRIAL , 1975, Annals of the New York Academy of Sciences.

[27]  G. Neil,et al.  L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine. , 1975, Cancer chemotherapy reports.

[28]  N. Kretchmer,et al.  A Review: Biological and Clinical Aspects of Pyrimidine Metabolism , 1974, Pediatric Research.

[29]  E. Sander,et al.  Noncompetitive inhibition by substituted sulfonamides of dihydroorotase from Zymobacterium oroticum. , 1973, Life sciences.

[30]  M. E. Jones,et al.  Uridylic acid synthesis in Ehrlich ascites carcinoma. Properties, subcellular distribution, and nature of enzyme complexes of the six biosynthetic enzymes. , 1973, Biochemistry.

[31]  G. Stark,et al.  Aspartate transcarbamylase. Interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate. , 1971, The Journal of biological chemistry.

[32]  R. Livingston,et al.  Glutamine antagonists in chemotherapy. , 1970, Advances in pharmacology and chemotherapy.

[33]  D. Pinkel,et al.  Chemotherapy with 6-azauridine (NSC-32074) for patients with leukemia. , 1969, Cancer chemotherapy reports.

[34]  R. W. Porter,et al.  Aspartate transcarbamylase. Kinetic studies of the catalytic subunit. , 1969, The Journal of biological chemistry.

[35]  H. Fallon,et al.  Summary of current information on 6-azauridine. , 1962, Cancer chemotherapy reports.

[36]  J. L. Way,et al.  The enzymatic synthesis of 5-fluorouridine 5'-phosphate. , 1959, The Journal of biological chemistry.

[37]  W. Holmes.  Studies on the mode of action of analogues of orotic acid; 6-uracilsulfonic acid, 6-uracilsulfonamide, and 6-uracil methyl sulfone. , 1956, The Journal of biological chemistry.